Alk-Abello AS (WBO:ALKB) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


WBO:ALKB Alk-Abello AS WBO:ALKB
66 GF Score
Price €34.22
GF Value €27.26
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Alk-Abello AS Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Alk-Abello AS's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

WBO:ALKB vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Alk-Abello AS's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alk-Abello AS Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Margin of Safety % (DCF Earnings Based) falls into.


WBO:ALKB
66GF Score
Alk-Abello AS WBO:ALKB
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alk-Abello AS (WBO:ALKB) Overvalued in 2026?

Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued. The current stock price of €34.22 is trading 25.5% above its estimated GF Value™ of €27.26. GuruFocus considers Alk-Abello AS to be Modestly Overvalued.

Key valuation signals for WBO:ALKB:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €27.26 vs. price of €34.22 (25.5% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the WBO:ALKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alk-Abello AS Business Description

Address Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
66GF Score

Get the complete analysis for WBO:ALKB

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.22
Price
€27.26
GF Value